Tirzepatide

(Mounjaro®)

Tirzepatide

Latest News

loading GIF

Drug updated on 4/17/2024

Dosage FormInjection (subcutaneous; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen)
Drug ClassGlucose-dependent insulinotropic polypeptides (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Tirzepatide (Mounjaro) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • A total of 17 systematic reviews/meta-analyses focused on the efficacy and safety of tirzepatide compared to other glucagon-like peptide-1 receptor agonists (GLP-1RAs) and various glucose-lowering treatments for adults with type 2 diabetes mellitus.
  • One study highlighted that tirzepatide was particularly effective in Japanese patients with type 2 diabetes, showing superior reductions in HbA1c levels and body weight compared to subcutaneous semaglutide and other GLP-1RAs.
  • Across multiple studies, it was noted that tirzepatide significantly reduced HbA1c levels and body weight when compared to both oral or subcutaneous semaglutides as well as other GLP-1RAs. The most significant reduction was observed at a dose of 15 mg.
  • Tirzepatide also showed superiority over basal insulin by offering more significant reductions in HbA1c levels along with fewer instances of hypoglycemia.
  • The drug's efficacy demonstrated a dose-response relationship; higher doses (10mg and 15mg) showed greater effectiveness than the lower one (5mg).
  • Tirzepatide has been associated with a higher incidence rate of gastrointestinal symptoms such as nausea, vomiting, decreased appetite, dyspepsia, constipation, and diarrhea when compared to placebo or any other GLP-1RAs. These side effects have shown dependence on dosage.
  • No increase in pancreatitis risk has been observed. However, a potential increased risk for gallbladder or biliary diseases requires attention during clinical practice.

Product Monograph / Prescribing Information

Document TitleYearSource
Mounjaro (tirzepatide) Prescribing Information.2023Lilly USA LLC, Indianapolis, IN

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.2024Diabetes, Obesity & Metabolism
Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis2024Pharmacological Research
Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.2023Diabetes Obesity and Metabolism
A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?.2023Frontiers in Endocrinology
Tirzepatide-induced gastrointestinal manifestations: A systematic review and meta-analysis. 2023Cureus
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: A systematic review and meta-analysis. 2023Frontiers in Endocrinology
Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. 2023Diabetology & metabolic syndrome
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: A systematic review and network meta-analysis. 2023EClinical Medicine
Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis. 2023Diabetes, Obesity & Metabolism
Semaglutide for the treatment of type 2 diabetes mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.2022Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis. 2022Frontiers in Pharmacology
Semaglutide for the treatment of type 2 diabetes mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.2022Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials. 2022Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis.2022Frontiers in Cardiovascular Medicine
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis.2022Diabetologia
Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis.2022Frontiers in Pharmacology
Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized phase II/III trials.2021Pharmaceuticals